Lineage Cell Therapeutics, Inc. (LCTX): Price and Financial Metrics

LCTX POWR Grades

• LCTX scores best on the Value dimension, with a Value rank ahead of 47% of US stocks.
• The strongest trend for LCTX is in Quality, which has been heading down over the past 52 weeks.
• LCTX ranks lowest in Momentum; there it ranks in the 8th percentile.

LCTX Stock Summary

• The capital turnover (annual revenue relative to shareholder's equity) for LCTX is 0.03 -- better than merely 8.7% of US stocks.
• LCTX's price/sales ratio is 95.55; that's higher than the P/S ratio of 96.77% of US stocks.
• LCTX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 7.44% of US stocks.
• Stocks that are quantitatively similar to LCTX, based on their financial statements, market capitalization, and price volatility, are ACAD, CSLT, TMDX, CLIR, and ACER.
• LCTX's SEC filings can be seen here. And to visit Lineage Cell Therapeutics Inc's official web site, go to www.lineagecell.com.

LCTX Valuation Summary

• LCTX's EV/EBIT ratio is -27.2; this is 192.83% lower than that of the median Healthcare stock.
• Over the past 243 months, LCTX's EV/EBIT ratio has gone down 13.5.
• LCTX's EV/EBIT ratio has moved down 13.5 over the prior 243 months.

Below are key valuation metrics over time for LCTX.

LCTX Growth Metrics

• Its year over year net income to common stockholders growth rate is now at 77%.
• Its 2 year price growth rate is now at -56.7%.
• The 2 year cash and equivalents growth rate now stands at -67.04%.

Over the past 52 months, LCTX's revenue has gone up $175,000.

The table below shows LCTX's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-09-30	3.528	-23.329	-11.995
2021-06-30	1.829	-23.328	-11.932
2021-03-31	1.703	-22.151	-13.666
2020-12-31	1.826	-19.753	-20.649
2020-09-30	2.712	-19.635	-27.163
2020-06-30	2.708	-22.231	-35.908

LCTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• LCTX has a Quality Grade of D, ranking ahead of 12.26% of graded US stocks.
• LCTX's asset turnover comes in at 0.015 -- ranking 380th of 682 Pharmaceutical Products stocks.
• INFI, ATHX, and TTNP are the stocks whose asset turnover ratios are most correlated with LCTX.

The table below shows LCTX's key quality metrics over time.